grade
pharmaceutical primary standard
API family
sulfadiazine
manufacturer/tradename
USP
mp
253 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
Nc1ccc(cc1)S(=O)(=O)Nc2ncccn2
InChI
1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)
InChI key
SEEPANYCNGTZFQ-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Sulfadiazine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Silver Sulfadiazine Cream
- Sulfadiazine
- Sulfadiazine Sodium
- Sulfadiazine Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under 磺胺嘧啶
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Chronic 2 - Repr. 2
存储类别
11 - Combustible Solids
U Kronawitter et al.
Deutsche medizinische Wochenschrift (1946), 118(46), 1683-1686 (1993-11-19)
A 45-year-old man with AIDS was treated for a recurrence of cerebral toxoplasmosis with sulphadiazine, 4 g, and pyrimethamine, 75 mg, daily. Owing to a lack of appetite and dysphagia he drank rather little water during the first week of
S Hoffmann
Scandinavian journal of plastic and reconstructive surgery, 18(1), 119-126 (1984-01-01)
Topical antibacterial treatment is of major importance in the burn patient. Silver sulfadiazine is an effective agent with low toxicity and few side effects. Deposition of silver in tissues, and absorption of sulfadiazine are both minimal. Present and future problems
L M Upton et al.
Antimicrobial agents and chemotherapy, 59(1), 490-497 (2014-11-12)
To achieve malarial elimination, we must employ interventions that reduce the exposure of human populations to infectious mosquitoes. To this end, numerous antimalarial drugs are under assessment in a variety of transmission-blocking assays which fail to measure the single crucial
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 1625009-200MG | 04061838747044 |